Orthobiologics

BONESUPPORT's bone graft substitutes are based on the patented CERAMENT technology platform. Direct sales commence in July 2020....

Results show that elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rates with i-FACTOR vs. allograft....

The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption...

Carmell will begin enrolling in a pivotal clinical program for Plasma-based Bioactive Material used in long-bone fractures as an adjunctive...

This represents the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft...

New preclinical data confirms that local delivery of a bisphosphonate in combination with CERAMENT can regenerate cancellous bone....

InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of...

BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S. ...

Bone Therapeutics received regulatory approvals for next studies of both of its lead therapeutic candidates to treat osteoarthritic knee pain....

BONESUPPORT will submit a De Novo application for approval of CERAMENT® G in the treatment of osteomyelitis. ...